Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

EVENITY DIN 02489597

Status: Marketed
Holder: AMGEN CANADA INC
Molecule: ROMOSOZUMAB
Available to quote

Health Canada record

Active ingredient(s)ROMOSOZUMAB 105 MG
Dosage formSolution
RouteSubcutaneous
SchedulePRESCRIPTION; SCHEDULE D
ClassHuman
ATCM05BX06 ROMOSOZUMAB
Original market date12-Aug-2019
Current status date12-Aug-2019
SourceHealth Canada DPD

Establishment licence of the holder

Amgen Canada Inc — licence 100048, currently licensed, last inspection rating C (2023-03-01).

No Canadian shortage report is currently matched to this DIN.

Notices of Compliance

NOCDateSubmissionReason
222912019-06-17New Drug Submission (NDS)
Request a quote for EVENITY

How to read a Canadian DIN record